Table 3.

Tumor response, PFS, and OS according to immune subtypes.

	Ayers IFNγ signature		Ayers expanded IFNγ signature		Thorsson six-class immune signature
Outcome (groups 2 and 3 vs. group 1)	High	Low	High	Low	Class 2	Not class 2
ORR, %	56.5 vs. 38.5	36.7 vs. 22.2	50.0 vs. 38.5	41.4 vs. 22.2	48.6 vs. 30.0	38.9 vs. 33.3
Median PFS, months	11.3 vs. 5.7	8.8 vs. 8.3	9.7 vs. 5.7	9.4 vs. 8.3	10.9 vs. 9.2	9.4 vs. 5.4
HR (95% CI)	0.49 (0.2–1.11)	0.87 (0.3–2.2)	0.47 (0.2–1.1)	1.1 (0.4–2.7)	0.69 (0.3–1.7)	0.76 (0.3–1.8)
Median OS, months	22.3 vs. 12.8	15.6 vs. 8.3	20.1 vs. 12.8	15.6 vs. 9.1	32.7 vs. 12.8	13.1 vs. 10.2
HR (95% CI)	0.40 (0.2–0.9)	0.37 (0.2–0.9)	0.41 (0.2–0.9)	0.40 (0.2–0.9)	0.46 (0.2–1.0)	0.49 (0.2–1.0)

Note: Group 1, chemotherapy on days 1 and 8; group 2, trilaciclib prior to chemotherapy on days 1 and 8; group 3, trilaciclib alone on days 1 and 8 and prior to chemotherapy on days 2 and 9. HRs are for comparisons between groups 2 and 3 combined and group 1. Class 2 was defined as IFNγ-dominant. Not adjusted for multiplicity.